Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Medium Chain Triglycerides (MCTs) have been explored as a supportive dietary intervention for Multiple Sclerosis (MS) based on their metabolic effects and potential neuroprotective properties. MCTs are rapidly absorbed fats that are converted into ketones in the liver, providing an alternative energy source for the brain. Since MS is characterized by neuroinflammation and demyelination, and some research suggests impaired glucose metabolism in the brains of people with MS, ketones from MCTs may help support neuronal energy demands.

A few small pilot studies and animal experiments have investigated ketogenic diets and MCT supplementation in MS. For example, a 2019 pilot study (Bricout et al.) found that a ketogenic diet including MCTs was safe and feasible in people with MS and reported some improvements in quality of life and fatigue, though the study was small and not blinded. Animal studies have suggested that ketones might reduce neuroinflammation and promote remyelination, but these findings have not been consistently replicated in humans. There is no robust, large-scale clinical trial evidence that MCTs directly alter disease progression in MS.

Thus, while there is a plausible scientific rationale and some early, limited evidence supporting the use of MCTs as an adjunct therapy for symptom management in MS, the evidence base remains preliminary. The current rating reflects that there is some scientific validation, but it is not yet strong or definitive.

More about Medium Chain Triglycerides
More about Multiple Sclerosis

Other ingredients used for Multiple Sclerosis

Other health conditions supported by Medium Chain Triglycerides

Products containing Medium Chain Triglycerides